This paper aims to discuss whether genetic polymorphisms of ARMS2 (rs10490924), VEGFA (rs3024997), TNFRSF1B (rs1061622), TNFRSF1A (rs4149576), and IL1B1 (rs1143623) and their serum biomarkers could confer susceptibility to early and exudative AMD with a response to anti-VEGF treatment. This evidence concerns the gene TNFRSF1A and age-related macular degeneration.